A BlueSky feed for the blog http://covalentmodifiers.blogspot.com. Discusses the covalent modification of proteins, particularly with regards to inhibitors.https://bsky.app/profile/covalentmod.bsky.socialhttps://bsky.app/profile/covalentmod.bsky.social/post/3mrd43g4rma2yCHARMM-GUI Covalent Ligand Docker as a Web-based Molecular Docking Platform for Covalent Ligands https://covalentmodifiers.blogspot.com/2026/07/charmm-gui-covalent-ligand-docker-as.html23 Jul 2026 15:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mrd43g4rma2yhttps://bsky.app/profile/covalentmod.bsky.social/post/3mraevwnfe425Covalent remodeling of CRBN creates a non-canonical neosubstrate interface with NTAQ1 https://covalentmodifiers.blogspot.com/2026/07/covalent-remodeling-of-crbn-creates-non.html22 Jul 2026 13:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mraevwnfe425https://bsky.app/profile/covalentmod.bsky.social/post/3mr2ch6qekc2yA covalent irreversible inhibitor binds in two mutually exclusive conformations to the active-site cysteine residue of human aldehyde dehydrogenase 1A3 https://covalentmodifiers.blogspot.com/2026/07/a-covalent-irreversible-inhibitor-binds.html20 Jul 2026 03:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mr2ch6qekc2yhttps://bsky.app/profile/covalentmod.bsky.social/post/3mquqqw46qr2yA covalent inhibitor targeting Cys-349 of LIMK1 confers selectivity over LIMK2 https://covalentmodifiers.blogspot.com/2026/07/a-covalent-inhibitor-targeting-cys-349.html17 Jul 2026 22:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mquqqw46qr2yhttps://bsky.app/profile/covalentmod.bsky.social/post/3mqnthv3vam24Machine learning-guided discovery of covalent sortase A inhibitors targeting MRSA virulence https://covalentmodifiers.blogspot.com/2026/07/machine-learning-guided-discovery-of.html15 Jul 2026 04:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mqnthv3vam24https://bsky.app/profile/covalentmod.bsky.social/post/3mnqs7tfgwb2kA chemoproteomic atlas of the human purine interactome for regioselective ligand discovery https://covalentmodifiers.blogspot.com/2026/06/a-chemoproteomic-atlas-of-human-purine.html08 Jun 2026 04:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mnqs7tfgwb2khttps://bsky.app/profile/covalentmod.bsky.social/post/3mmkr654h4z2wCharacterization of the Second-Generation Covalent Fragment Library (CovLib Gen2): Thiol Reactivity Profiling and p53-Y220C Rescue https://covalentmodifiers.blogspot.com/2026/05/characterization-of-second-generation.html24 May 2026 01:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mmkr654h4z2whttps://bsky.app/profile/covalentmod.bsky.social/post/3mmdqjsydj42wAccelerating SuFEx Reactions via Aryl Fluorosulfate Structural Engineering for Enhanced Covalent Targeted Cancer Therapy https://covalentmodifiers.blogspot.com/2026/05/accelerating-sufex-reactions-via-aryl.html21 May 2026 06:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mmdqjsydj42whttps://bsky.app/profile/covalentmod.bsky.social/post/3mlhrdtdn4i2gCovalent Inhibitors of Monoacylglycerol Lipase Induce Conformational Changes and Proteasomal Degradation https://covalentmodifiers.blogspot.com/2026/05/covalent-inhibitors-of-monoacylglycerol.html10 May 2026 03:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mlhrdtdn4i2ghttps://bsky.app/profile/covalentmod.bsky.social/post/3mldvc5zr3k2pDevelopment and Structural Characterization of UTE-156, a Covalent Inhibitor of the VCP/p97 AAA+ ATPase https://covalentmodifiers.blogspot.com/2026/05/development-and-structural.html08 May 2026 14:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mldvc5zr3k2phttps://bsky.app/profile/covalentmod.bsky.social/post/3mldrwviyo224Nitro-Diphenyl Ethers as Emerging Cysteine-Targeting Covalent Warheads Enable Identification of Novel Target LDLRAP1 for Anticoronaviral Activity https://covalentmodifiers.blogspot.com/2026/05/nitro-diphenyl-ethers-as-emerging.html08 May 2026 13:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mldrwviyo224https://bsky.app/profile/covalentmod.bsky.social/post/3mlc4cb2yn424Shifting the PPARγ conformational ensemble toward a transcriptionally repressive state improves covalent inhibitor efficacy https://covalentmodifiers.blogspot.com/2026/05/shifting-ppar-conformational-ensemble.html07 May 2026 21:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mlc4cb2yn424https://bsky.app/profile/covalentmod.bsky.social/post/3ml7f4rkptf2pDon’t Lose Your (War)head: Structure–Activity Relationships of Covalent Warheads as Substrates for GST-Catalyzed Glutathione Conjugation https://covalentmodifiers.blogspot.com/2026/05/dont-lose-your-warhead.html06 May 2026 19:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3ml7f4rkptf2phttps://bsky.app/profile/covalentmod.bsky.social/post/3ml5e6n55fs2vDeciphering covalent kinase inhibitor binding landscape through structural kinome profiling https://covalentmodifiers.blogspot.com/2026/04/deciphering-covalent-kinase-inhibitor.html05 May 2026 23:37 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3ml5e6n55fs2vhttps://bsky.app/profile/covalentmod.bsky.social/post/3ml5e6mystp2pData-driven design of chiral covalent fragments using highthroughput chemoproteomics and machine learning https://covalentmodifiers.blogspot.com/2026/04/data-driven-design-of-chiral-covalent.html05 May 2026 23:37 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3ml5e6mystp2phttps://bsky.app/profile/covalentmod.bsky.social/post/3ml5e6mug5l2kElectrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability https://covalentmodifiers.blogspot.com/2026/04/electrophilic-compound-screening.html05 May 2026 23:37 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3ml5e6mug5l2khttps://bsky.app/profile/covalentmod.bsky.social/post/3ml5e6mpx752gA Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning https://covalentmodifiers.blogspot.com/2026/05/a-novel-covalent-inhibitor-fragment-for.html05 May 2026 23:37 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3ml5e6mpx752ghttps://bsky.app/profile/covalentmod.bsky.social/post/3ml5e6mlc5t2kEfficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study https://covalentmodifiers.blogspot.com/2026/05/efficacy-and-safety-of-branebrutinib.html05 May 2026 23:37 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3ml5e6mlc5t2khttps://bsky.app/profile/covalentmod.bsky.social/post/3mhxxx5pvs427A Fragment Screen Identifies Acrylamide Covalent Inhibitors of the TEAD•YAP Protein-Protein Interaction https://covalentmodifiers.blogspot.com/2026/03/a-fragment-screen-identifies-acrylamide.html26 Mar 2026 16:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mhxxx5pvs427https://bsky.app/profile/covalentmod.bsky.social/post/3mht5pvmhzs2jDiscovery of Covalent Ligands with AlphaFold3 https://covalentmodifiers.blogspot.com/2026/03/discovery-of-covalent-ligands-with.html24 Mar 2026 18:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mht5pvmhzs2jhttps://bsky.app/profile/covalentmod.bsky.social/post/3mhqnay5g7h24Acrylamide Bioisosterism: Alkenyl Aromatic Heterocycles as Reactivity-Tunable Warheads for Covalent BTK Inhibitors https://covalentmodifiers.blogspot.com/2026/03/acrylamide-bioisosterism-alkenyl.html23 Mar 2026 18:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mhqnay5g7h24https://bsky.app/profile/covalentmod.bsky.social/post/3mhodin7aho2kCovalent JAK3 inhibitors based on 2-arylamino and 7H-pyrrolo[2,3-d]pyrimidine scaffold: design, synthesis, and biological evaluation for the potential treatment of Bortezomib-resistant multiple myeloma https://covalentmodifiers.blogspot.com/2026/03/covalent-jak3-inhibitors-based-on-2.html22 Mar 2026 20:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mhodin7aho2khttps://bsky.app/profile/covalentmod.bsky.social/post/3mguo2xxeoh2uA Global Ligandability Map of Tryptoline Butynamide Stereoprobes Identifies Covalent Inhibitors of the Actin Maturation Protease ACTMAP https://covalentmodifiers.blogspot.com/2026/03/a-global-ligandability-map-of.html12 Mar 2026 15:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mguo2xxeoh2uhttps://bsky.app/profile/covalentmod.bsky.social/post/3mgtci7y4lm2uDevelopment and Structural Characterization of UTE-156, a Covalent Inhibitor of the VCP/p97 AAA+ ATPase https://covalentmodifiers.blogspot.com/2026/03/development-and-structural.html12 Mar 2026 02:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mgtci7y4lm2uhttps://bsky.app/profile/covalentmod.bsky.social/post/3mgaxqrgquu2fDiscovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C https://covalentmodifiers.blogspot.com/2026/03/discovery-and-characterization-of.html04 Mar 2026 19:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mgaxqrgquu2fhttps://bsky.app/profile/covalentmod.bsky.social/post/3mfcosfym7s2fA Tandem Bioorthogonal Retro-Cope and Cope Elimination for the Activation of Covalent Inhibitors with an Acrylamide or Vinylsulfonamide Warhead in Live Cells https://covalentmodifiers.blogspot.com/2026/02/a-tandem-bioorthogonal-retro-cope-and.html20 Feb 2026 18:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mfcosfym7s2fhttps://bsky.app/profile/covalentmod.bsky.social/post/3mf7xmwvpam2eDiscovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8 https://covalentmodifiers.blogspot.com/2026/02/discovery-of-potent-selective-and-in.html19 Feb 2026 16:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mf7xmwvpam2ehttps://bsky.app/profile/covalentmod.bsky.social/post/3mewtwuwdaa2yExploiting human fucosyltransferase 8 allostery with a covalent inhibitor for core fucosylation suppression https://covalentmodifiers.blogspot.com/2026/02/exploiting-human-fucosyltransferase-8.html16 Feb 2026 01:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3mewtwuwdaa2yhttps://bsky.app/profile/covalentmod.bsky.social/post/3me7yzxy52f2nCovalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C https://covalentmodifiers.blogspot.com/2026/02/covalent-inhibitor-design-confers.html06 Feb 2026 23:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3me7yzxy52f2nhttps://bsky.app/profile/covalentmod.bsky.social/post/3me5f7r2gmx2yDevelopment of a Lysine-Reactive Targeted Covalent Inhibitor (TCI) for the P300/CBP-Associated Factor (PCAF) Bromodomain Through Structure-Based Design https://covalentmodifiers.blogspot.com/2026/02/development-of-lysine-reactive-targeted.html05 Feb 2026 22:00 +0000at://did:plc:7h2tk3fyncbpmsvwlrpv5m6a/app.bsky.feed.post/3me5f7r2gmx2y